Anti-gout drugs: study of assortment, socio-economic availability and consumption levels in Ukraine




gout, anti-gout drugs, social and economic availability, consumption levels


Topicality. Gout is a chronic systemic metabolic disease, accompanied by hyperuricemia, arthritis and deposition in tissues and internal organs of urates with the formation of gout nodules. In the complex pharmacotherapy of gout patients, the main group for aetiotropic treatment are anti-gout drugs (AGD).

Aim. To study the assortment, social and economic availability and consumption of AGD in Ukraine for 2014-2016.

Materials and methods. The analysis of AGD range was carried out according to the information retrieval system “Pharmstandard” of the company “Morion”, consumption – by the indicator DDDs/1000 inhabitants/day, economic accessibility – by the indicator of Ca.s., which shows the share of wages in % that is spent for a monthly course of treatment.

Results and discussion. The assortment of AGD in the pharmaceutical market of Ukraine in 2014-2016 is quite limited and is presented by 7-10 trade names (TN) based on 2-4 INN. The most consumed and available for a monthly course of treatment for gout patients were the PPP of allopurinol, presented in a larger number of TNs on the pharmaceutical market in Ukraine.

Conclusions. Despite the insignificant assortment of AGD in the pharmaceutical market of Ukraine, their consumption for 2014-2016 corresponded to the number of gout patients (0.5-2.8 % of the population) in Ukraine. 

Author Biographies

O. V. Tkachova, National University of Pharmacy

doctor of Pharmaceutical Sciences, associate professor of the Department of Pharmacoeconomics

I. S. Serdyuk, National University of Pharmacy

5-th year student of “Clinical pharmacy” specialty


Kuo, C.–F., Grainge, M. J., Zhang, W., Doherty, M. (2015). Global epidemiology of gout: prevalence, incidence and risk factors. Nature Reviews Rheumatology, 11 (11), 649–662. doi: 10.1038/nrrheum.2015.91

Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda–Sanabria, J., Bardin, T. (2016). 2016 updated EULAR evidence–based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76 (1), 29–42. doi: 10.1136/annrheumdis–2016–209707

Denisov, I.S., Eliseev, M. S., Barskova, V. S. (2013). Nauchno–prakticheskaia revmatologiia, 51 (5), 569–573.

Povorozniuk, V. V., Dubetska, H. S. (2012). Problemy osteolohii, 15 (3), 19–25.

Moroz, H. Z. (2010). Terapiia, XIII (74), 14–16.

Barskova, V. G., Ilina, A. E. (2010). Klinitcist, 1, 78–80.

Barskova, V. G., Eliseev, M. S., Denisov, I. S. et al. (2012). Nauchno–prakticheskaia revmatologiia, 50 (60), 15–18.

Korzh, A. N., Krasnokutskyi, S. V. (2015). Skhidnoievropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny, 1, 40–47.

Yakovlieva, L. V., Mishchenko, O. Ya., Adonkina, V. Yu. (2017). Farmakoepidemiolohichni doslidzhennia obsiahiv spozhyvannia antyhipertenzyvnykh likarskykh zasobiv v Ukraini. Kharkiv: NUPh, 108.

10. Derzhavna sluzhba statystyky Ukrainy. Available at:

Morozov, A. M., Yakovlevа, L. V., Stepanenko, A. V. et al. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo–terapevtychno–khimichnoiu klasyfikatsiieiu za vstanovlenymy dobovymy dozamy. Kharkiv: Styl–Izdat, 34.





Pharmacology and biochemistry